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To theEditor—We thank Dr. Srinivas [1]
for his interest in our recent review article
[2] and appreciate the opportunity to re-
spond to his thoughtful comments.
We agree that interactions between ri-
fampin and other medications, including
antiretrovirals, can be clinically or phar-
macologically unpredictable and that
close monitoring of patients taking rifam-
pin with other medications is essential [3,
4]. Srinivas brings to light an interesting
mechanism—inhibition of hepatic up-
take via blockage of organic anion trans-
port— by which rifampin may cause
acute paradoxical drug interactions. He
further reminds us that the complexity of
drug interactions with rifampin is com-
pounded when the companion drug’s
metabolite is pharmacologically active, as
is the case with nelfinavir. It is fortunate,
however, that the hepatic transporter
blockade drug-drug interaction mecha-
nism he describes appears to be rare, af-
fecting only a few drugs, most of which
are not commonly used in resource-
limited settings. It is also fair to say that
this type of interaction is unlikely to occur
with antiretrovirals, the vast majority of
which have been evaluated in drug-drug
interaction studies with rifampin. In ad-
dition, given that the interaction he de-
scribes results in higher plasma concen-
trations of a coadministered drug, the
potential impact on antiretrovirals may
not be deleterious.
The comments by Srinivas are timely
and serve as a much-needed reminder
that mechanisms for drug interactions are
increasingly complex and that clinicians
need to maintain vigilance whenever add-
ing drugs to an existing regimen.
Kelly E. Dooley,1,2 Charles Flexner,2 and
Adriana S. Andrade1
Divisions of 1Infectious Diseases and 2Clinical
Pharmacology, Department of Medicine, Johns
Hopkins University, Baltimore, Maryland
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To the Editor—Regan et al. [1] predict
that Chlamydia trachomatis prevalence in
women in Australia will fall by 70% in
10 years with a screening program that
tests 30% of 15–24-year-olds each year.
This means that 70% of the target popu-
lation would remain untested every year
and that participants would be tested, on
average, once every 3 years. This is an op-
timistic view of the impact that limited
screening coverage would have, given the
absence of evidence that opportunistic
testing at this level has controlled chla-
mydia transmission up to now [2]. We
think that there are reasons for caution in
using predictions from this model to in-
form decisions on “the most effective
chlamydia screening program for Austra-
lia” [1, p. 357].
First, the inability to model long-term
partnerships explicitly in this compart-
mental model is a fundamental limitation
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that makes predictions about reductions
in prevalence unreliable. Reinfection of
the index case patient from a current un-
treated sex partner cannot be taken into
account in Regan et al.’s model because
the model does not keep track of ongoing
partnerships and all infected individuals
are returned to the susceptible state, after
either treatment or natural clearance of
infection [1]. Within an ongoing partner-
ship, reinfection can take place if the part-
ner is not treated along with the index
case patient. In this model, repeat infec-
tions only occur in subsequent partner-
ships. In reality, early reinfection with
chlamydia after screening and treatment
of an individual who has untreated part-
ners is common [3]. Regan et al. assert
that “screening . . . will be the primary in-
tervention in Australia” [1, p. 357]. They
assume that their model provides a con-
servative estimate of the effect of a chla-
mydia screening intervention because
partner notification would provide addi-
tional benefits compared with those of
screening alone. This can be shown to be
the case when the impact of chlamydia
screening is investigated in an individual-
based model, because the net effect of
screening without partner notification
takes into account the reinfection of index
case patients in partnerships in which the
partner was not screened [4]. Additional
partner-notification efforts then have an
incremental effect. Regan et al.’s com-
partmental model, however, overesti-
mates the effect of chlamydia screening
because it ignores reinfections that do not
contribute to reducing prevalence. After
dissolution of the old partnership and
formation of a new partnership, the infec-
tion could be transmitted to a new sex
partner. The impact of ignoring reinfec-
tion would be greater when only one sex is
screened and at low levels of coverage.
Second, predicted reductions in chla-
mydia prevalence cannot currently be
used as a proxy for the overall effective-
ness of a chlamydia screening program. A
proxy (or surrogate marker) has to have a
known relationship with the outcome [5].
The primary objective of chlamydia
screening programs is to prevent compli-
cations, such as tubal infertility, that re-
sult from chlamydia infections that as-
cend to damage the upper genital tract
[2]. It is not known, however, whether
there is a relationship between increasing
screening coverage and reducing female
reproductive tract morbidity.
Regan et al.’s model is more complex
than some other compartmental models
of C. trachomatis transmission [6] and
might be useful for examining the relative
importance of different strategies, but it
cannot be used to quantify the effects of
different levels of screening coverage ac-
curately. The need for empirical studies
that demonstrate the impact of chlamydia
screening programs on both chlamydia
transmission and the incidence of com-
plications remains [2]. Mathematical
models that dynamically incorporate the
progression to fertility-related complica-
tions of chlamydia are needed to help
understand the impact of screening pro-
grams on primary outcomes [7, 8]. Fur-
ther methodological studies that directly
compare the assumptions and predic-
tions of compartmental and individual-
based models to help us understand how
reinfection and partner notification affect
the incidence and prevalence of chla-
mydia are also needed. We suggest that it
is premature for health policy makers to
base decisions about chlamydia screening
programs on this mathematical model,
which does not represent the dynamics of
chlamydia transmission adequately.
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Reply to Low et al.
To the Editor—In our article [1], we de-
scribed the results from a compartmental
model of chlamydia transmission in a het-
erosexual population. We calibrated our
model using the best Australian epidemi-
ological and behavioral data available as
well as biological data from the literature.
The stated primary aims of our work were
to compare various screening strategies in
terms of their effectiveness in reducing
the incidence and prevalence of chla-
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